These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20431556)

  • 1. Trial watch: dual inhibition shows promise in hypertension.
    Nat Rev Drug Discov; 2010 May; 9(5):350. PubMed ID: 20431556
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin receptor neprilysin inhibition for the treatment of hypertension: the neglected child in cardiovascular pharmacotherapy.
    Kjeldsen SE; Atar D; von Lueder TG
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):122-123. PubMed ID: 30698668
    [No Abstract]   [Full Text] [Related]  

  • 3. Blood-pressure reduction with LCZ696.
    Waeber B; Feihl F
    Lancet; 2010 Apr; 375(9722):1228-9. PubMed ID: 20236699
    [No Abstract]   [Full Text] [Related]  

  • 4. Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation.
    Zern EK; Cheng S; Wolfson AM; Hamilton MA; Zile MR; Solomon SD; Kittleson MM
    Circ Heart Fail; 2020 Feb; 13(2):e006696. PubMed ID: 32059634
    [No Abstract]   [Full Text] [Related]  

  • 5. Sacubitril-Valsartan for the Treatment of Heart Failure: Time for a Paragon?
    Del Buono MG; Bonaventura A; Vecchié A; Wohlford GF; Dixon DL; Van Tassel BW; Abbate A
    J Cardiovasc Pharmacol; 2020 Feb; 75(2):105-107. PubMed ID: 31815825
    [No Abstract]   [Full Text] [Related]  

  • 6. PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction.
    Docherty KF; McMurray JJV
    Cardiovasc Res; 2019 Nov; 115(13):e136-e139. PubMed ID: 31497841
    [No Abstract]   [Full Text] [Related]  

  • 7. In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure?
    Bonaventura A; Wohlford GF; Vecchié A; Van Tassel BW; Abbate A
    J Cardiovasc Pharmacol; 2019 Jul; 74(1):1-3. PubMed ID: 31274835
    [No Abstract]   [Full Text] [Related]  

  • 8. Is sacubitril/valsartan safe for treatment of hypertension at any age?
    De Vecchis R; Ariano C
    J Cardiovasc Med (Hagerstown); 2019 Jan; 20(1):49. PubMed ID: 30320726
    [No Abstract]   [Full Text] [Related]  

  • 9. Is the glass half full or half empty after PARAGON-HF?
    Cohen-Solal A; Logeart D
    Cardiovasc Res; 2020 Jan; 116(1):e5-e7. PubMed ID: 31850504
    [No Abstract]   [Full Text] [Related]  

  • 10. Sacubitril/valsartan (Entresto) for heart failure.
    Med Lett Drugs Ther; 2015 Aug; 57(1474):107-9. PubMed ID: 26218791
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat.
    Rubattu S; Cotugno M; Forte M; Stanzione R; Bianchi F; Madonna M; Marchitti S; Volpe M
    J Hypertens; 2018 Sep; 36(9):1902-1914. PubMed ID: 29916993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confirmatory Trials for Drugs Approved on a Single Trial.
    Haslam A; Prasad V
    Circ Cardiovasc Qual Outcomes; 2019 Jun; 12(6):e005494. PubMed ID: 31137954
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
    Gori M; Volterrani M; Piepoli M; Senni M
    Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological and clinical properties of AIMIX® combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate].
    Mori M; Takahashi S
    Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):39-46. PubMed ID: 23842227
    [No Abstract]   [Full Text] [Related]  

  • 15. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.
    Ruilope LM; Dukat A; Böhm M; Lacourcière Y; Gong J; Lefkowitz MP
    Lancet; 2010 Apr; 375(9722):1255-66. PubMed ID: 20236700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
    Uijl E; 't Hart DC; Roksnoer LCW; Groningen MCC; van Veghel R; Garrelds IM; de Vries R; van der Vlag J; Zietse R; Nijenhuis T; Joles JA; Hoorn EJ; Danser AHJ
    J Hypertens; 2020 Apr; 38(4):755-764. PubMed ID: 31790054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness of antihypertensive treatment and control of blood pressure: is it improvable?].
    Sierra C; Ruilope LM
    Med Clin (Barc); 2013 Oct; 141(8):343-5. PubMed ID: 23831401
    [No Abstract]   [Full Text] [Related]  

  • 18. Lowering blood pressure in acute stroke: the SCAST trial.
    Hankey GJ
    Lancet; 2011 Feb; 377(9767):696-8. PubMed ID: 21316753
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
    Chrysant SG
    J Am Soc Hypertens; 2017 Jul; 11(7):461-468. PubMed ID: 28652105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
    Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.